PF Products & Features GmbH Bolsters Cardiac Portfolio with AVVie Acquisition

P&F Products & Features GmbH Strengthens Its Cardiac Portfolio with AVVie Acquisition

On August 5, 2026, PF Products & Features GmbH (PF) announced the acquisition of AVVie GmbH, a company known for its innovative technologies in the field of structural heart diseases. This strategic move is set to significantly reinforce PF's portfolio, particularly with the introduction of the AngelValve™ system, an innovative transcather solution designed to address mitral regurgitation, a prevalent heart condition.

With more than 13 million people in Europe and the United States suffering from mitral regurgitation, PF recognizes the urgency in providing effective treatment options, especially when only 5% of patients with moderate to severe forms currently receive any form of treatment. This acquisition aligns with PF's mission to bridge this therapeutic gap and ultimately enhance the quality of life for millions affected.

Founded by the acclaimed cardiac surgeon Professor Werner Mohl, AVVie has been at the forefront of developing cutting-edge solutions for detecting and treating heart valve diseases. The AngelValve™ platform is tailored to meet unmet needs for patients who have limited or no therapeutic options available. By integrating AVVie’s research and development infrastructure with PF's extensive global capabilities in product development, clinical affairs, regulatory affairs, manufacturing, and marketing, the newly formed entity promises to accelerate innovation and streamline product development timelines effectively.

Dr. Katharina Kiss, CEO of PF, stated, "The acquisition of AVVie highlights our unwavering commitment to pioneering innovative treatments for structural heart diseases. Merging AVVie’s technical excellence with our clinical development expertise places us in an advantageous position to advance the AngelValve™ platform and deliver significant innovations to healthcare providers and patients globally. This acquisition marks a pivotal step in realizing our ambition to emerge as a global leader in treating structural heart diseases."

Siegfried Einhellig, Chief Operations Officer at PF, echoed this sentiment, emphasizing the exceptional engineering talents brought together through this alliance. He added, “We are excited to bring this innovation to effective treatment options for those suffering from mitral valve pathologies.”

The financial terms of the acquisition remain undisclosed, but the implications for the industry are significant. PF Products & Features GmbH, headquartered in Vienna, Austria, boasts over 25 years of experience in developing innovative cardiovascular solutions and operates in approximately 70 countries with production facilities in Europe, Asia, and Brazil.

As the healthcare industry continually shifts towards innovative and effective treatment options, this acquisition represents a forward-thinking move by PF. By strengthening its capabilities in addressing structural heart diseases, PF is well-positioned to play a vital role in transforming patient care and outcomes. As the health sector embraces cutting-edge technology, the combination of PF and AVVie exemplifies the future of medical advancements.

For more information about PF Products & Features GmbH’s innovative offerings and initiatives, visit productsandfeatures.com.